Alembic Pharmaceuticals · NSE: APLLTD · BSE: 533573

Q1 FY23 results · Apr–Jun 2022

Alembic Pharmaceuticals reported revenue from operations of ₹1,262.14 crore (down 4.8% from Q1 FY22) and net loss of ₹65.90 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	1,262.14	1,326.03	−4.8%	1,415.74	−10.8%
Other income	1.08	1.88	−42.5%	10.27	−89.5%
Total income	1,263.22	1,327.91	−4.9%	1,426.01	−11.4%
Profit before share of associates & JVs and tax	(60.16)	182.54	Turned loss	40.59	Turned loss
Share of profit/(loss) of associates & JVs	(7.22)	9.92		(11.94)
Net profit for the period	(65.90)	158.27	Turned loss	30.39	Turned loss
Attributable to shareholders of the company	(65.88)	164.52	Turned loss	35.46	Turned loss
EPS, basic (₹)	(3.35)	8.37	Turned loss	1.80	Turned loss
Net margin (%)	-5.2	11.9		2.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY23	Q1 FY22	YoY	Q4 FY22	QoQ
Revenue from operations	1,160.33	1,269.69	−8.6%	1,304.32	−11.0%
Other income	0.62	1.74	−64.1%	11.59	−94.6%
Total income	1,160.95	1,271.43	−8.7%	1,315.91	−11.8%
Profit before tax	72.46	233.19	−68.9%	251.03	−71.1%
Net profit for the period	72.46	192.69	−62.4%	251.37	−71.2%
EPS, basic (₹)	3.69	9.80	−62.4%	12.79	−71.2%
Net margin (%)	6.2	15.2		19.3

Consolidated

Filed with BSE: 05 Aug 2022, 10:24 IST
Board meeting: 04 Aug 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 05 Aug 2022, 10:24 IST
Board meeting: 04 Aug 2022
Period: 01 Apr 2022 to 30 Jun 2022
Review status: Unaudited
Source: XBRL filing on BSE